Patanjali Foods Hits Record On Plans To Buy Sister Unit's Non-Food Business
Patanjali Foods has entered the business transfer agreement with the sister company to buy its non-food business undertakings such as haircare, skincare, dentalcare, and homecare for Rs 1,100 crore.
Patanjali Foods Ltd. rose to a record high on Tuesday after its board approved the acquisition of Patanjali Ayurved Ltd.'s entire non-food business for Rs 1,100 crore.
The non-food business of sister company Patanjali Ayurved includes haircare, skincare, dentalcare, and homecare, according to an exchange filing. The total acquisition amount will be paid in five tranches of 20%, 20%, 45%, 10%, and 5%, the filing said. The transaction falls under the related-party transaction category as Patanjali Foods is one of the promoters of Patanjali Ayurved.
As part of the deal, the company will also acquire Patanjali Ayurved's moveable assets, immovable properties, assumed liabilities, contracts, licenses, books, and records, the exchange filing said. This acquisition will likely increase the product portfolio of Patanjali Foods.
However, the Securities and Exchange Board of India must approve the acquisition.
The company has also entered into a license agreement with Patanjali Ayurved to obtain rights to use the latter's licensed intellectual properties, according to an exchange filing on Monday.
Patanjali Foods To Buy Patanjali Ayurved's Home And Personal Care Business For Rs 1,100 Crore
.png?auto=format%2Ccompress)
Shares of Patanjali Foods rose 3.83% to Rs 1,764.40, the highest level since it was listed on Jan 24, 2020. It was trading 1.11% higher at Rs 1,718.60 apiece as of 10:12 a.m., compared with a 0.02% decline in the benchmark BSE Sensex.
The stock gained 43.07% in last 12 months and 8.41% on year to date basis. Total traded volume so far in the day stood at 18 times its 30-day average. The relative strength index was at 72.80, which implied the stock is overbought.
Both the analysts tracking the stock maintain a 'buy' rating, according to Bloomberg data. The average 12-month consensus price target implies a downside of 0.1%.
